Modeling the Cost Effectiveness of Secondary Febrile Neutropenia Prophylaxis During Standard-Dose Chemotherapy

Timmer-Bonte, Johanna N.H.; Adang, Eddy; Termeer, Evelien; Severens, Johan L.; Tjan‐Heijnen, Vivianne C. G.

doi:10.1200/jco.2007.13.0898

Cited by 26 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toevaluatecostsfromthehospitalprovider [15,17].Similartoourresults,arecentlypublishedSpanishretrospective study reports FN-related costs depending on tumour type [10]. Costs were highest if NHL was the underlying cancer (€ 4,514).…”

Section: Data Collectionmentioning

confidence: 72%

Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer

Ihbe-Heffinger

Paessens²,

Schilling

et al. 2011

Onkologie

View full text Add to dashboard Cite

Background: Febrile neutropenia/leukopenia (FN/FL) is the most frequent dose-limiting toxicity of myelosuppressive chemotherapy, but German data on economic consequences are limited. Patients and Methods: A prospective, multicentre, longitudinal, observational study was carried out to evaluate the occurrence of FN/FL and its impact on health resource utilization and costs in non-small cell lung cancer (NSCLC), lymphoproliferative disorder (LPD), and primary breast cancer (PBC) patients. Costs are presented from a hospital perspective. Results: A total of 325 consecutive patients (47% LPD, 37% NSCLC, 16% PBC; 46% women; 38% age = 65 years) with 68 FN/FL episodes were evaluated. FN/FL occurred in 22% of the LPD patients, 8% of the NSCLC patients, and 27% of the PBC patients. 55 FN/FL episodes were associated with at least 1 hospital stay (LPD n = 34, NSCLC n = 10, PBC n = 11). Mean (median) cost per FN/FL episode requiring hospital care amounted to € 3,950 (€ 2,355) and varied between € 4,808 (€ 3,056) for LPD, € 3,627 (€ 2,255) for NSCLC, and € 1,827 (€ 1,969) for PBC patients. 12 FN/FL episodes (LPD n = 9, NSCLC n = 3) accounted for 60% of the total expenses. Main cost drivers were hospitalization and drugs (60 and 19% of the total costs). Conclusions: FN/FL treatment has economic relevance for hospitals. Costs vary between tumour types, being significantly higher for LPD compared to PBC patients. The impact of clinical characteristics on asymmetrically distributed costs needs further evaluation.

show abstract

Section: Data Collectionmentioning

confidence: 72%

Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer

Ihbe-Heffinger

Paessens²,

Schilling

et al. 2011

Onkologie

View full text Add to dashboard Cite

show abstract

“…26 We commonly observe CSFs being misused in support of low-risk combination therapies ranging from adjuvant therapy for breast cancer to the treatment of metastatic colorectal cancer. ASCO guidelines allow the use of CSFs to avoid hospitalization for patients with febrile neutropenia, but in many settings reducing the chemotherapy dose or administering prophylactic antibiotics 27 represents a common alternative approach.…”

Section: Changing Oncologists’ Behaviormentioning

confidence: 99%

Bending the Cost Curve in Cancer Care

2011

View full text Add to dashboard Cite

“…26 We commonly observe CSFs being misused in support of lowrisk combination therapies ranging from adjuvant therapy for breast cancer to the treatment of metastatic colorectal cancer. ASCO guidelines allow the use of CSFs to avoid hospitalization for patients with febrile neutropenia, but in many settings reducing the chemotherapy dose or administering prophylactic antibiotics 27 represents a common alternative approach.…”

Section: Reducing Chemotherapy Dose In Metastatic Solid Cancersmentioning

confidence: 99%

Bending the Cost Curve in Cancer Care

Field¹,

Faragher²,

Gibbs³

2011

N Engl J Med

View full text Add to dashboard Cite

Modeling the Cost Effectiveness of Secondary Febrile Neutropenia Prophylaxis During Standard-Dose Chemotherapy

Abstract: This model-based economic analysis demonstrates that in the Netherlands and most likely also in the United States, if secondary prophylaxis is preferred, the strategy with antibiotics is recommended.

Cited by 26 publications

References 22 publications

Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer

Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer

Bending the Cost Curve in Cancer Care

Bending the Cost Curve in Cancer Care

Contact Info

Product

Resources

About